



Fourth Quarter and Full-Year 2022 Financial Results and Business Update

April 25, 2023

Alexander Zehnder

Business Update

Chief Executive Officer

Myriam Mendila

Program Update

Chief Development Officer

Pierre Kemula

Financial Update

Chief Financial Officer



The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Dr. Alexander Zehnder

 **Global Head of Oncology**, Sanofi, Boston, U.S.


 President & Managing Director, Sanofi Italy & Malta

 President & Managing Director, Roche Greece & Cyprus

 Vice President, Global Product Strategy, Roche/Genentech, San Francisco, U.S.

 Avastin Life Cyclor Leader, Global Product Strategy, Roche/Genentech, San Francisco, U.S.

 Life Cyclor Leader Japan, Chugai (Roche Group), Tokyo, Japan

 A trained physician with a track record of building pipelines, shaping organizations and delivering results

Dr. Myriam Mendila



Chief Medical Officer & Global Head Oncology Medical Affairs,
Novartis Pharma, Switzerland



Senior Vice President, Head U.S. Medical Affairs and Regional Medical Director North America, Genentech, San Francisco, U.S.



Senior Vice President, Head Global Medical Affairs, Product Development, Roche, Basel, Switzerland



Vice President, Global Head Hematology and Skin Cancer Franchise, Global Product Strategy, Genentech, San Francisco, U.S.



Life Cyclor Leader Avastin, Global Product Strategy, Roche, Basel, Switzerland



Clinical Science Leader MabThera/Oncology, Product Development, Basel, Roche, Switzerland



A trained physician with more than 20 years of experience in bringing medical innovation to patients

2022 Selected Key Achievements



Clinical Development




4 clinical trials in **COVID-19** and **flu**

Selection of **modified mRNA** candidates in Jan 2023



Validated mRNA Platform



Oncology Expansion



Acquisition of **Frame Cancer Therapeutics**

State-of-the-art technologies

Strategic partnership with **myNEO**



Differentiated Antigen Discovery



Corporate Development

Growing the talent base: **>1,100** employees



New sites

Digitizing the organization



Ongoing Business Transformation



Manufacturing Landscape



German **Pandemic Preparedness** Agreement

GMP IV

commercial-scale



The RNA Printer® personalized therapy scale

Seamless Scalability



Financial Execution

Strong cash position of **€495.8 million¹⁾**





Capital raise of **\$250 million** in Feb 2023

Robust Financing


CureVac Pipeline: A Diversified Portfolio

AREA	PROGRAM		CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	
PROPHYLACTIC VACCINES	2 nd -Generation	COVID-19		CV2CoV (unmodified mRNA)				
				CV0501 (modified mRNA)				
	2 nd -Generation Infectious Diseases	Influenza		CVSQIV (unmodified mRNA)				
				FLU SV mRNA (modified mRNA)				
		Other		Four undisclosed targets				
	1 st -Generation	Rabies		CV7202				
Diverse Projects			Rota, malaria, universal influenza					
ONCOLOGY	Solid tumors ¹⁾		CV8102					
	Neoantigens		Antigen discovery engine based on new technologies acquired with Frame Cancer Therapeutics					
	Tumor Associated Antigens							
MOLECULAR THERAPY	Cas9 gene-editing		CRISPR Therapeutics collaboration					
	Liver Diseases		REBIRTH-Research Center collaboration					
	Ocular Diseases		Schepens Eye Research Institute collaboration					
	Therapeutic Antibodies		Genmab collaboration					






Reactogenicity in younger adults (age 18-64)




Reactogenicity in older adults (age ≥65)



CV0501: Modified mRNA

GMI against BA.1, both age groups, Day 15 and 29 (Younger adults 18-64, older adults ≥65)

Dose	Day 15 GMI	Day 29 GMI
3 µg (only YA) NEW	4.8 (n=15)	n/a
6 µg (only YA) NEW	4.9 (n=15)	n/a
12 µg	10.5 (n=30)	9.5 (n=30)
25 µg	11.1 (n=29)	10.5 (n=28)
50 µg	12.1 (n=30)	10.6 (n=30)
100 µg NEW	12.4 (n=29)	11.4 (n=26)
200 µg NEW	21.8 (n=26)	14.6 (n=18)



Upcoming Phase 1 Proof-of-Principle Study Patients with surgically resected glioblastoma

- Study expected to start in Q2 2023 in up to 54 patients
- Construct encoding eight epitopes from tumor associated antigens
- Assessing safety, immunogenicity and T cell response of second-generation mRNA backbone in oncology setting
- Clinical sites in Germany, Belgium and the Netherlands
- First data read-out expected in H2, 2024

Prophylactic Vaccines

- Strong **humoral responses**, induction of **antibodies**
- High **tolerability**, minimize side effects and reactogenicity
- High **stability** for easy large-scale delivery and **long-term storage**

Cancer Vaccines


- Strong **cellular responses**, induction of **tumor-killing T cells**
- Strong systemic activation of **signaling pathways** to maximize immune response
- Maximized **mRNA uptake** into immune cells for highest **efficacy**

LNP: Tailoring Biological Activity for Improved Prophylactic and Cancer Vaccines


Testing LNPs with varying components and concentrations

In vitro stimulation of immune signaling activity in human PBMCs


Cytokine:
IFN- α 2




Inflammation marker:
IL-6



CD80 marker:
monocyte activation



CD80 marker:
pDC activation






Strong induction of
cytokines


T cell relevant immune
signaling pathways

Strong induction of
innate immune cells

Highly Flexible Manufacturing Landscape Serving Different Lifecycle Needs

		Research, Technology & Development	Technical Development	Inhouse plants GMP I to III	Inhouse plant GMP IV <i>In the build up</i>	The RNA Printer® <i>In regulatory approval</i>
FLEXIBILITY		mRNA design	Preclinical studies	Clinical studies / early commercial production	Commercial production	Personalized therapy
SCALABILTY		Digital sequence	mg-scale / annual output	g to kg-scale / annual output	multi kg-scale / annual output	Individual dosing
SPEED		+++	+++	+	++	++++

Solid Financing Position to Support Corporate Development



Cash and Condensed Consolidated P&L Data



	December 31, 2022	December 31, 2021
(in € millions)		
Cash and Cash Equivalents	495.8	811.5

	Three months ended December 31,		Twelve months ended December 31,	
(in € millions)	2022	2021	2022	2021
Revenue	11.7	41.2	67.4	103.0
Cost of Sales, Operating Expenses & Other Operating Income	-133.2	-46.7	-316.9	-515.3
Operating Result	-121.5	-5.5	-249.5	-412.3
Financial Result	-7.2	1.0	0.3	-0.2
Pre-Tax Loss	-128.7	-4.5	-249.2	-412.5



2022, **transformational year**, driven by successful initiation of COVID-19 and flu **clinical developments** and strong expansion of **oncology footprint**



In early 2023, **critical validation** of CureVac's proprietary technology platform opens new chapter in the company's **corporate evolution**




Continued clinical development in COVID-19 and flu with two new studies according to state-of-the-art formats and tailored toward **public health needs**



First **oncology study** on track to kick off cancer vaccine developments, supported by strong **complementary LNP technologies** for further technology **differentiation**



Strong year-end cash position of €495.8 million supported by recent raise of \$250 million extend cash reach to **mid-2025** and supports executing on programs and priorities





**Thank you for your
attention**

CureVac
www.curevac.com